GlassScriptPhysician profile
Steven Michael Schadendorf
NPI 1619926102
$3,620.35
in general payments reported to CMS, 2019-2025
40 companies · $1,056 in 2025
The $1,056 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $287 · 2020: $140 · 2021: $351 · 2022: $306 · 2023: $631 · 2024: $849 · 2025: $1,056.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,436 · Education: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,436.46 |
| Education | $100.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $845.17 | 2021-2025 | Botox, Ubrelvy, Qulipta |
| Ucb, INC. | $228.20 | 2023-2025 | Zilbrysq, Nayzilam, Briviact |
| Merz Pharmaceuticals, LLC | $211.55 | 2023-2025 | Xeomin, Inbrija |
| Biogen, INC. | $186.86 | 2019-2023 | Vumerity, Avonex |
| Lilly USA, LLC | $179.95 | 2022-2025 | Kisunla, Amyvid, Emgality |
| Alexion Pharmaceuticals, INC. | $172.74 | 2019-2025 | Ultomiris |
| Teva Pharmaceuticals USA, INC. | $159.27 | 2019-2024 | Austedo Xr |
| Novartis Pharmaceuticals Corporation | $156.44 | 2019-2025 | |
| Kyowa Kirin, INC. | $107.52 | 2020-2023 | Nourianz |
| Argenx US, INC. | $104.28 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Allergan, INC. | $97.12 | 2019-2021 | |
| Genentech USA, INC. | $74.08 | 2022-2023 | Ocrevus, Enspryng |
| Amgen INC. | $72.27 | 2024-2025 | Uplizna |
| Eisai INC. | $70.16 | 2023-2025 | |
| Lundbeck LLC | $68.78 | 2024-2025 | Vyepti |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Schadendorf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.